On November 17, 2017 Novogen reprorted that following the Company’s Annual General Meeting held on Wednesday 15 November, where shareholders voted to approve all resolutions, the Company is pleased to advise that the name Kazia Therapeutics Limited has been formally adopted after registration by ASIC (Press release, Kazia Therapeutics, NOV 17, 2017, View Source [SID1234525997]). The ASX has been informed and the Company will trade under the new ticker of KZA from Tuesday 21 November 2017. The Company will also trade under the NASDAQ ticker of KZIA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO Dr James Garner said: "Our new brand, Kazia Therapeutics, reflects the innovative, focused and agile company that we have become. I am delighted that shareholders voted in support of our new name and future."